Subscribe to receive this daily commentary directly in your email
MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN SHARES OF TSLA, GOOGL, AAPL
Good Morning Today is Monday, January 7
- S&P 500 futures are pointing to a lower opening of 2 points as of 7:50 AM
- The US 10-year rate is at 2.64%
- Dollar Index is at 95.94
- WTI Crude Oil is $49.14
- Gold:$1,292
- VIX: 22.92
- Critical events for today: Eli Lilly to buy Loxo Oncology for $8 billion, China and US resume trade talks, ISM Services Index estimates of 58.4
Recap of International Trading:
- Hong Kong Hang Seng Index up 0.82%
- Japan up 2.44%
- China Shanghai Comp. up 0.72%
- UK FTSE down 0.48%
- Dax down 0.47%
S&P 500 (SPY)
Independent macro and options research, published every trading day — $85/mo or $750/yr
Subscribe →Stocks are flat on the day but there is plenty of bullish news around today especially out of biotech was the JP Morgan Health Care conference kick’s – off.
Biotech (XBI)
Biotech stocks are getting a lift on some positive headlines. The XBI ETF is likely to rise to around $79.
Navigating The Market · By Michael Kramer
Independent macro and options research, published every trading day.
Daily written analysis covering gamma exposure, dealer flows, key levels, and the macro drivers moving markets. Includes full video access.
Recent Subscriber Analysis
- One Last Pay-Down Boost Before The Bill-Issuance Drain Begins
- Reading a Geopolitical Setup — Oil Through the Iran Cycle
- Rates Break The Multi-Year Downtrend, And Only 0DTE Flow Is Holding Stocks Up
- End Of Dispersion Hands The Market Back To Macro And Liquidity
- Bonds And Stocks Price Oil As A Non-Event While Dispersion Unwinds As Expected
Eli Lilly/ Loxo
Eli Lilly is buying Loxo Oncology for $8 billion or $235 per share. Loxo had been trading at $139.87 on Friday. The shares are trading higher to $221
Alphabet (GOOGL)
Pivotal Research upgraded Alphabet to buy from hold and placed a $1240 price target on the stock. A rise above $1,100 would trigger a breakout and a potential move to $1,175
Amazon (AMZN)
Pivotal also initiated coverage of Amazon with a $1920 price target. For now, resistance remains around $1620.
Salesforce (CRM)
Pivotal also upgrade Salesforce to buy with a $164 price target. Resistance comes around $149.
Tesla (TSLA)
Tesla broke ground in China to build its Giga factory and expects to start Model 3 production later this year. The stocks next level of resistance will come around $340.
The Market Chronicles · Video Membership
The daily market commentary, delivered in video.
Same daily market analysis, in video form — available to YouTube channel members only.
Latest Videos
Apple (AAPL)
Apple will now offer iTunes Movies and shows on Samsung tvs. Apple has room to fill the gap at around $157.
Exact Sciences
Exact Sciences is surging premarket after pre-announcing its fourth quarter guidance, raising revenue guidance to $143 million at the mid-point from $127.4 million. Should the stock increases above $68.25 it has room to go higher to around $70.
Sage Therapeutics (SAGE)
Sage is jumping by 33% today after the company reported positive data on its drug SAGE-217 in female patients with severe postpartum depression. $140 is resistance for the stock.
Micron (MU)
Micron Upgraded to Outperform from Market Perform at BMO. $34 is the next immediate level of resistance.
Mike
This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.
One Last Pay-Down Boost Before The Bill-Issuance Drain Begins
Mott Capital's Market Chronicles 20 hours ago